A Phase 3 interventional study of Retatrutide in Obesity and Overweight, sponsored by Eli Lilly and Company. Active, not recruiting at 35 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's planned enrollment of 600 is above the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Have a Body Mass Index (BMI) at screening
Exclusion Criteria:
Have had within the past 90 days before screening:
Participants will receive retatrutide subcutaneously (SC)
Drug: Retatrutide
Participants will receive retatrutide SC
Drug: Retatrutide
Participants will receive retatrutide SC
Drug: Retatrutide
Administered SC
Also known as: LY3437943
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 104
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 104
Percent Change from Baseline in Triglycerides
Time frame: Baseline, Week 104
Change from Baseline in Systolic Blood Pressure
Time frame: Baseline, Week 104
Percent Change from Baseline in High Sensitivity C-Reactive Protein
Time frame: Baseline, Week 104
Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT) Total Score
Time frame: Baseline, Week 104
Overall Treatment Satisfaction with Medication for Obesity (TS-MO) Scores
Time frame: Week 104
Pharmacokinetics (PK): Steady state Average Trough PK Concentration
Time frame: Baseline through Week 104
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Sap, Csr
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company